Abstract:e13014 Background: The goal of this study was to determine the role of ATP7A in the platinum resistance of esophageal squamous cell carcinoma (ESCC) and non-small cell lung cancer (NSCLC). Methods: Platinum drugs' sensitivities were determined by MTT assay; multidrug resistance-related genes were analyzed by RT-PCR and immunoblotting. After Silencing ATPA in DDP-resistant cell sublines by siRNA, the changes in DDP sensitivies were determined by MTT assay and flow cytometry. The expression of ATP7A in clinical specimens of NSCLC patients who only received chemotherapy was evaluated by immunohistochemistry,and associations were sought between ATP7A expression and the clinicopathologic characteristics. Results: A549/DDP and EC109/DDP cell lines showed more resistant to DDP than A549 and EC109 cell lines, it also showed cross resistance to CBDCA and L-OHP. The expression of ATP7A was significantly higher in the A549/DDP and EC109/DDP than A549 and EC109 cell lines at both mRNA and protein levels. SiRNA duplexs targeting ATP7A was added into the A549/DDP and EC109/DDP cells, which successfully inhibited ATP7A expression, partially reversed DDP-resistance and increased cell death at different DDP concentrations. ATP7A was detected in 41.6% of 89 unresectable NSCLC patients who had only received platinum-based chemotherapy. The ATP7A-positive patients had a significantly lower histological grade (p=0.039) and worse response to platinum-based chemotherapy (p= 0.001) compared with the ATP7A-negative patients. Furthermore, the patients whose tumor tissue were ATP7A positive had a significantly poorer overall survival (p=0.021). Cox's proportional hazards model analysis showed ATP7A was a significantly independent factor for overall survival (p=0.045). Conclusions: ATP7A high expression plays an important role in platinum-resistance of ESCC and NSCLC, and could be a prognostic factor for NSCLC patients treated with platinum-based chemotherapy. Our study provided a new understanding of platinum resistance in ESCC and NSCLC and may have implications for therapeutic reversal of drug resistance. No significant financial relationships to disclose.

Copper Efflux Transporters ATP7A and ATP7B: Novel Biomarkers for Platinum Drug Resistance and Targets for Therapy

Copper-Transporting P-Type Adenosine Triphosphatase (atp7a) is Associated with Platinum-Resistance in Non-Small Cell Lung Cancer (Nsclc)

The Role of Copper Transporter ATP7A in Platinum-Resistance of Esophageal Squamous Cell Cancer (ESCC).

The Role of a Copper Transporter, ATP7A, in Platinum Resistance of Esophageal Squamous Cell Cancer (ESCC) and Non-Small Cell Lung Cancer (NSCLC).

Gene Expression and Single Nucleotide Polymorphism of ATP7B Are Associated with Platinum-Based Chemotherapy Response in Non-Small Cell Lung Cancer Patients.

Nanoparticle Delivery of a Triple-Action Pt(iv) Prodrug to Overcome Cisplatin Resistance Via Synergistic Effect

[Expression of Copper-Transporting P-Type Adenosine Triphosphatase (ATP7B) Correlates with Cisplatin-Resistance in Human Lung Adenocarcinoma Cell Line A549.].

Ammonium Tetrathiomolybdate Treatment Targets the Copper Transporter Atp7a and Enhances Sensitivity of Breast Cancer to Cisplatin

Copper transporter gene ATP7A: A predictive biomarker for immunotherapy and targeted therapy in hepatocellular carcinoma

ATP7B Rs9535826 is Associated with Gastrointestinal Toxicity of Platinum-Based Chemotherapy in Nonsmall Cell Lung Cancer Patients

ATP 11 B Mediates Platinum Resistance in Ovarian Cancer

miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).

ATPase Copper Transporting Beta (ATP7B) is a Novel Target for Improving the Therapeutic Efficacy of Docetaxel by Disulfiram/Copper in Human Prostate Cancer.

The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.

Targeting the Copper Transport System to Improve Treatment Efficacies of Platinum-Containing Drugs in Cancer Chemotherapy

MiR-495 Inhibits Cisplatin Resistance and Angiogenesis in Esophageal Cancer by Targeting ATP7A

Pan-cancer analysis reveals copper transporters as promising potential targets

Research Progress on Copper Ion Transport Protein Family and Cisplatin Drug Resistance in Lung Cancer

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Association Between Polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and Platinum Resistance in Epithelial Ovarian Cancer

Identification of Three Potential Prognostic Genes in Platinum-Resistant Ovarian Cancer Via Integrated Bioinformatics Analysis.